JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• A Safety Study of 2 Formulations of GlaxoSmithKline Biologicals' (GSK's) Human Rotavirus (HRV) Vaccine in Healthy Infants of Age 6-12 Weeks

  NCT03954743

  Condition:   Infections, Rotavirus
  Interventions:   Biological: HRV Liquid;   Biological: HRV Lyophilized
  Sponsor:   GlaxoSmithKline
  Recruiting
• Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology

  NCT03699514

  Conditions:   Healthy;   Cognitive Impairment;   Neurological Disorder
  Intervention:   Device: Brain Network Activation (BNA™) technology
  Sponsor:   ElMindA Ltd
  Recruiting
• Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

  NCT04084769

  Condition:   Meningococcal Infection (Healthy Volunteers)
  Interventions:   Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal Group B Vaccine (Trumenba®);   Biological: Meningococcal group B Vaccine (Bexsero®)
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• A Study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged Release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

  NCT04085172

  Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
  Interventions:   Drug: Guanfacine hydrochloride (SPD503);   Drug: Atomoxetine hydrochloride;   Other: Placebo
  Sponsor:   Shire
  Recruiting
• Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

  NCT04007991

  Condition:   Tourette Syndrome in Children; Tourette Syndrome in Adolescents
  Intervention:   Drug: Ecopipam
  Sponsor:   Emalex Biosciences Inc.
  Recruiting
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

  NCT03979313

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: MEDI8897;   Drug: Placebo
  Sponsor:   MedImmune LLC
  Recruiting
• A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

  NCT03924323

  Conditions:   Anxiety Disorders;   Generalized Anxiety Disorder
  Interventions:   Drug: Escitalopram;   Other: Placebo
  Sponsor:   Allergan
  Recruiting
• Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

  NCT03673462

  Condition:   Healthy Volunteers (Meningococcal Infection)
  Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine);   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®);   Biological: Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine;   Biological: Varicella Virus Vaccine
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

  NCT03653364

  Condition:   Influenza
  Intervention:   Drug: Baloxavir Marboxil
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

  NCT03597503

  Condition:   Attention Deficit Hyperactivity Disorder
  Interventions:   Drug: SPN-810;   Drug: Placebo
  Sponsor:   Supernus Pharmaceuticals, Inc.
  Recruiting
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder

  NCT03569475

  Condition:   Major Depressive Disorder
  Interventions:   Drug: Levomilnacipran ER;   Drug: Fluoxetine;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Dextromethorphan Pediatric Acute Cough Study

  NCT02651116

  Condition:   Cough
  Interventions:   Drug: Dextromethorphan Hydrobromide;   Drug: Placebo;   Device: Cough recording device
  Sponsor:   Pfizer
  Recruiting
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

  NCT03893448

  Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
  Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

  NCT03813238

  Condition:   Cerebral Palsy, Dyskinetic
  Interventions:   Drug: Deutetrabenazine;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  NCT03661866

  Conditions:   Atopic Dermatitis;   Alopecia;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

  NCT03633617

  Condition:   Eosinophilic Esophagitis
  Interventions:   Drug: Dupilumab;   Drug: Placebo
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma

  NCT03595124

  Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Axitinib;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Long Term Safety Study of BCX7353 in Hereditary Angioedema

  NCT03472040

  Conditions:   Hereditary Angioedema;   HAE;   Prophylaxis
  Intervention:   Drug: BCX7353
  Sponsor:   BioCryst Pharmaceuticals
  Recruiting
• Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

  NCT03428646

  Condition:   Dermatitis, Atopic
  Intervention:   Drug: Dupilumab
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

  NCT03148418

  Condition:   Cancer
  Intervention:   Drug: Atezolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• OPsumit USers Registry

  NCT02126943

  Condition:   Pulmonary Arterial Hypertension
  Intervention:   Drug: Opsumit (macitentan)
  Sponsor:   Actelion
  Recruiting
• Product Surveillance Registry

  NCT01524276

  Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
  Intervention:  
  Sponsor:   Medtronic
  Recruiting